Implementation of the Affordable Care Act in 2010 introduced significant change in health care in the United States. Some of the changes seen by many as desirable included elimination of lifetime maximum benefits, elimination of discrimination for pre-existing conditions, and the ability of young adults to stay on their parents' insurance until age 26.
The election of a new president, who took office in early 2017, introduced much speculation about what would happen, including speculation that the Affordable Care Act would be repealed. The first attempt failed, but what will be next? And, how will it impact the American people? Hospitals across the country are facing increasing financial burden. Meanwhile, patients continue to require care and we are challenged to continue providing high quality care as we navigate the changes in how care is reimbursed. For patients with chronic conditions or those with long-term treatment plans, their care is at risk of interruption or changes in reimbursement with the changes imposed by the legislature.
This session will highlight changes that have occurred or are expected to occur based on legislative action in early 2017. Examples will be shared specific to pediatric hematology/oncology patients, as available. Additionally, discussion will occur regarding new, expensive therapies and the challenges in obtaining preauthorization from third party payors to be able to provide these innovative therapies to patients.
As a result, pediatric hematology/oncology nurses will have a better understanding of the financial challenges faced by their patients and families, as well as the challenges associated with being able to offer new and often expensive state-of-the-art therapy. Understanding the ever-changing financial climate faced by healthcare organizations and patients and families will assist nurses in providing care in a world of constant change.
- Opening Keynote: Secrets Everyone in Health Care Needs to Know (101)
- General Session: International Pediatric Hematology/Oncology Nursing Initiatives: Challenges and Opportunities (102)
- It's All GREEK To Me! The NEPENTHE Trial for Relapsed/Refractory Neuroblastoma; Personalized Molecularly Targeted Treatment (200)
- A Sustainable Community Engagement Program Model to Address Hematopoietic Cell Transplantation Education Needs for Patients with Sickle Cell Disease (201)
- Nursing Management for the Successful Application of the Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy (212)
- Kaye Schmidt, MA RN NEA-BC CPON®